Analysis of ongoing ABX203 Phase IIb/III trial in chronic hepatitis B virus infection shows good safety, but primary endpoint of study is unlikely to be reached

June 17, 2016
PDF Version
Details
Published on Friday, 17 June 2016 18:00

·Post-treatment monitoring of the patients will be continued as per protocol in order to provide additional insight on clinical trial outcomes and secondary endpoints 

·Future development of ABX203 under review, including the addition of an adjuvant, new administration schedules and therapeutic combinations

·Ongoing anti-HIV ABX464 Phase IIa trial progressing well

·Four additional product candidates in pipeline

Paris, June 17, 2016 - ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative company developing anti-viral therapies and immunotherapeutics for infectious diseases like HIV/AIDS, chronic hepatitis B (CHB), chikungunya, ebola as well as an adjuvant to enhance the immune response,  today announced that a futility analysis on the primary end-point  of its ABX203-002 trial, a Phase IIb/III trial of ABX203 in CHB patients, determined that the trial is unlikely to reach its primary endpoint.